



UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./	FILING DATE	FIRST NAMED INVENTOR /	ATTORNEY DOCKET NO.
CONTROL NO.		PATENT IN REEXAMINATION	

EXAMINER

ART UNIT

PAPER

200504

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The term "synthetic" (SEQ ID NO 1, section <213> has been deleted from the CRF and needs to be deleted from the paper copy of the sequence listing. Regarding SEQ. Ids 6-9, section <213> should describe only the organism (or artificial). Further information regarding the name of the molecule can be described in section <223> (see MPEP section 2424 and 2431).

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Ron Schwadron, Ph.D. Primary Examiner Art Unit 1644 571 272 0851

> RONALD B. SCHWADROH PRIMARY EXAMINER

GROUP 1800 (600)

PTO-90C (Rev.04-03)

01	Notice to Comply	Application No. 09925284	Applicant(s) Hawiger et al.			
MAY 0		Examiner Ron Schwadron, Ph.D.	Art Unit 1644			
TRAD	Ron Schwadron, Ph.D. 1644 NCICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQU There is also no support in the specification as originally filed fo ENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)). The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).					

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer

content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the

6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the

1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

For questions regarding compliance to these requirements, please contact:

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or

readable form must be submitted as required by 37 C.F.R. 1.825(d).

"Sequence Listing" as required by 37 C.F.R. 1.821(e).

specifically directing its entry into the specification.

For Rules Interpretation, call (571) 272-2510

PatentIn Software Program Support

For CRF Submission Help, call (571) 272-2501/2583.

7. Other: see enclosed communication.

Applicant Must Provide:

1.825(d).

37 C.F.R. 1.821(e).